{"contentid": 488721, "importid": NaN, "name": "Breakthrough designation for Boehringer\u00e2\u0080\u0099s drug for cognitive impairment associated with schizophrenia", "introduction": "The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for Boehringer Ingelheim\u00e2\u0080\u0099s BI 425809 for the treatment of cognitive impairment associated with schizophrenia (CIAS).", "content": "<p>The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for Boehringer Ingelheim&rsquo;s BI 425809 for the treatment of cognitive impairment associated with schizophrenia (CIAS).</p>\n<p>The privately-held German company also announced the planned initiation of the innovative CONNEX Phase III trial assessing the safety and efficacy of BI 425809 for improving cognition in adults with schizophrenia.</p>\n<p>BI 425809, a glycine transporter-1 (GlyT1) inhibitor, forms a key component of Boehringer's Mental Health research program.</p>\n<p>This Breakthrough Therapy Designation and the Phase III trial initiation are based on results from the Phase II 1346.9 clinical trial, which demonstrated that BI 425809 improved cognition in adult patients with schizophrenia.</p>\n<p>Central to many everyday tasks, impairment of cognitive function is a major burden for people with schizophrenia, and no pharmacological treatments are currently approved for CIAS.</p>\n<p>Vikas Mohan Sharma, head of medicine CNS, retinopathies and emerging areas, Boehringer, said: &ldquo;Cognition is a fundamental aspect of everyday life, including problem solving, memory and attention, which is why finding solutions for cognitive impairment is a key area of Boehringer Ingelheim Mental Health research.</p>\n<p>&ldquo;This Breakthrough Therapy Designation further highlights the urgent need for novel treatments for people living with schizophrenia. By combining traditional treatment approaches with new and innovative technologies, we are developing targeted therapies that will help to ease the burden of mental health conditions and enable people living with these conditions to create more meaningful connections to their lives, loved ones and society.&rdquo;</p>", "date": "2021-05-24 17:59:00", "meta_title": NaN, "meta_keywords": "schizophrenia, Breakthrough, impairment, designation, cognitive, Boehringer, drug, Therapy, treatment, CIAS, Boehringer\u00e2\u0080\u0099s, Food, Administration, granted", "meta_description": "The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Boehringer Ingelheim\u00e2\u0080\u0099s BI 425809 for the treatment of cognitive", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-24 17:56:51", "updated": "2021-05-24 19:35:06", "access": NaN, "url": "https://www.thepharmaletter.com/article/breakthrough-designation-for-boehringer-s-drug-for-cognitive-impairment-associated-with-schizophrenia", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "boehringer_aerial_large.jpg", "image2id": "boehringer_aerial_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Cognitive disorders, Schizophrenia", "sector_tag": "Biotechnology", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "Germany", "company_tag": "Boehringer Ingelheim", "drug_tag": "BI 425809", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-24 17:59:00"}